Loading…

Apotea ABAPOTEA.STCompetitor analysis, valuation and peers

Sweden · SEK·Consumer Discretionary›Specialty Stores
Momentum leader 96
Mkt cap
$1.11B
US dollars, full cap
Free float
51%
of shares outstanding
$/day
$3.42M
20-day average traded
Fwd P/E
37.2×
forward earnings
ROIC−WACC
+15.9 pp
WACC 5.0%
Hurdle
-1 pp
Req g minus delivered
Next earnings
90 days
4 Feb 2027
Close · SEKSEK 104.30
1D+1.3%
1W+13.2%
1M+22.7%
3M+44.6%
6M+41.7%
YTD+13.1%
1Y+29.7%
ATR %2.6%
52w lowhigh1.1% off high

What Apotea does

Employees: 969

Apotea at a glance

Size Apotea (APOTEA.ST) is a Sweden Consumer Discretionary company (Specialty Stores) with a market value of $1.11B, the 129th largest of 221 Sweden companies the cockpit tracks. Shares closed at SEK 104.30 on 6 Nov 2026.

Performance Over six months the shares gained 41.7%, against -7.2% for the median peer and +8.2% for the Sweden market (cap-weighted) — highest of 20 in its peer set.

Growth Revenue grew 9.3% over the last twelve months (peer median +5.6%); the operating margin is 4.0% (peer median 5.0%).

Valuation It trades at 37.2× forward earnings against a peer median of 14.8× (3rd most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 15.9 points above its cost of capital (5.0% WACC).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014011 May 202611 Aug 20266 Nov 2026APOTEA.ST 141Peer median 93
Six months, rebased to 100: Apotea against the median of its 20 peers (local-currency closes).

Apotea financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
RevenueSEK 7.59BSEK 7.20BSEK 6.54BSEK 5.45B
Revenue growth—+10%+20%—
Gross profitSEK 304MSEK 302MSEK 257MSEK 97.4M
EBITDASEK 502MSEK 459MSEK 384MSEK 216M
Net incomeSEK 246MSEK 229MSEK 215MSEK 87.0M
Free cash flowSEK 153MSEK 120MSEK 43.4MSEK 95.9M
Capital expenditureSEK 83.3MSEK 216MSEK 164MSEK 121M
Total debtSEK 279MSEK 331MSEK 242MSEK 262M

Quarterly statements and history in the cockpit →

Apotea competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%01169690BLUESTONE600335HZO000026PET3010783186002818DOURUSTA257720CWCPNGJLBILI-A68088133SYNSAMAPOTEA.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Apotea is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×50×100×01169690BLUESTONEHZO000026PET3010783186002818DOU257720CWCPNGJLAPOTEA.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Apotea is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%9690600335000026PET3010783186DOURUSTA2577206808SYNSAMAPOTEA.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Apotea is the large dot.

Apotea competitors and peer comparison

How Apotea compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Apotea against its 20 peers (data as of 6 Nov 2026)
MeasureAPOTEA.STPeer medianRank in peer set
1-month return+22.7%-0.1%highest of 21
6-month return+41.7%-7.2%highest of 20
Distance from 52-week high-1.1%-27.4%highest of 21
Revenue growth (TTM)+9.3%+5.6%8th highest of 21
Operating margin4.0%5.0%9th lowest of 20
Forward P/E37.2×14.8×3rd most expensive of 17
Growth the price implies (Req g, 7 yrs)7.9%-2.3%most demanding of 16
Growth delivered (Del g)+9.4%+6.0%6th highest of 16
Hurdle (Req g minus delivered)-1.5 pp-6.7 pp3rd most demanding of 16
ROIC minus cost of capital+15.9 pp+4.3 pp2nd highest of 19
EV / EBITDA22.0×7.1×2nd most expensive of 12
Net debt / EBITDA0.3×1.6×6th least indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Apotea APOTEA.STSweden$1.11B+42%+9%4%37.2×7.9%+9.4%
Chow Sang Sang Holdings International 0116.HKHong Kong$1.13B+7%+16%20%3.1×n/an/a
TUHU Car 9690.HKHong Kong$1.14B-13%+16%0%21.3×-17.8%+12.7%
Bluestone Jewellery and Lifestyle BLUESTONE.NSIndia$1.15B+41%+38%9%132.9×n/an/a
Sinomach Automobile 600335.SSChina$1.16B-14%-11%2%n/a-10.9%-4.2%
MarineMax HZOUnited States$1.16B+21%-6%2%32.8×n/an/a
FIYTA Precision Technology 000026.SZChina$1.05B+1%+2%n/a52.4×5.3%-3.8%
Pet Valu PET.TOCanada$1.03B+6%+6%16%13.0×-3.5%+12.6%
Kidswant Digital Technology 301078.SZChina$1.24B-25%+5%5%21.8×-0.6%+4.2%
Nextage 3186.TJapan$1.25B-26%+24%4%11.2×-0.1%+22.0%
Chengdu Fusen Noble-House Industrial 002818.SZChina$1.26B-8%-22%42%11.2×-2.7%-1.0%
Douglas DOU.DEGermany$976M-7%+1%4%6.7×-1.1%+7.6%
Rusta RUSTA.STSweden$1.28B-17%+8%8%18.7×2.5%+7.3%
SILICON 2 257720.KSSouth Korea$1.30B-39%+55%19%7.2×-14.8%+62.2%
CEWE Stiftung & Co. KGaA CWC.DEGermany$926M+11%+4%11%10.1×-2.3%+3.5%
P N Gadgil Jewellers PNGJL.NSIndia$919M-17%+51%6%15.9×n/an/a
Bilia BILI-A.STSweden$1.37B+9%+1%3%14.6×0.9%+6.0%
Sun Art Retail 6808.HKHong Kong$1.37B-24%-10%0%n/a1.6%-9.4%
Augmont Enterprises AUGMONT.NSIndia$892Mn/a+42%0%n/an/an/a
Itochu Enex 8133.TJapan$1.41B+3%+2%3%n/a-7.1%+2.9%
Synsam SYNSAM.STSweden$868M+13%+9%10%15.0×-4.4%+10.2%

Questions

Which companies are Apotea's closest peers?
The cockpit's peer set: Chow Sang Sang Holdings International (0116.HK), TUHU Car (9690.HK), Bluestone Jewellery and Lifestyle (BLUESTONE.NS), Sinomach Automobile (600335.SS), MarineMax (HZO), FIYTA Precision Technology (000026.SZ), Pet Valu (PET.TO), Kidswant Digital Technology (301078.SZ).
Is Apotea expensive compared with its peers?
On forward p/e it trades at 37.2× against a peer median of 14.8×, 3rd most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has Apotea stock performed?
Over six months to 6 Nov 2026 the shares returned +41.7% against -7.2% for the median peer; over one year +29.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.